These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7914109)

  • 1. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
    Boesch D; Loor F
    Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
    Boesch D; Muller K; Pourtier-Manzanedo A; Loor F
    Exp Cell Res; 1991 Sep; 196(1):26-32. PubMed ID: 1879470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.
    Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F
    Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
    Jachez B; Nordmann R; Loor F
    J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives.
    Jachez B; Boesch D; Grassberger MA; Loor F
    Anticancer Drugs; 1993 Apr; 4(2):223-9. PubMed ID: 7683935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
    Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
    Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
    Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
    Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
    Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
    Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
    Lehne G; De Angelis P; den Boer M; Rugstad HE
    Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.
    Didier A; Loor F
    Anticancer Drugs; 1996 Sep; 7(7):745-51. PubMed ID: 8949985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
    Didier A; Wenger J; Loor F
    Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
    Tiberghien F; Loor F
    Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents.
    Jachez B; Cianfriglia M; Loor F
    Anticancer Drugs; 1994 Dec; 5(6):655-65. PubMed ID: 7534147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDZ 280-125: a cyclopeptolide endowed with an in vitro cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells.
    Jachez B; Boesch D; Emmer G; Loor F
    Anticancer Drugs; 1994 Jun; 5(3):313-20. PubMed ID: 7919456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
    Jonsson B; Nilsson K; Nygren P; Larsson R
    Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
    Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
    J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
    Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
    Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.